<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bacterial meningitis in children older than one month: Treatment and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bacterial meningitis in children older than one month: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bacterial meningitis in children older than one month: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Children with suspected bacterial meningitis require urgent evaluation and management, including prompt administration of appropriate antimicrobial therapy  (<a class="graphic graphic_table graphicRef74865" href="/z/d/graphic/74865.html" rel="external">table 1</a>). The mortality rate of untreated bacterial meningitis approaches 100 percent. Even with optimal therapy, morbidity and mortality may occur. Neurologic sequelae are common among survivors.</p><p>The treatment and prognosis of bacterial meningitis in infants and children older than one month will be reviewed here. Other aspects of bacterial meningitis in pediatric patients are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical features, evaluation, and diagnosis (see  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial meningitis in neonates (see  <a class="medical medical_review" href="/z/d/html/6005.html" rel="external">"Bacterial meningitis in the neonate: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6016.html" rel="external">"Bacterial meningitis in the neonate: Treatment and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/6017.html" rel="external">"Bacterial meningitis in the neonate: Neurologic complications"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic complications (see  <a class="medical medical_review" href="/z/d/html/6000.html" rel="external">"Bacterial meningitis in children: Neurologic complications"</a> and  <a class="medical medical_review" href="/z/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pathophysiology (see  <a class="medical medical_review" href="/z/d/html/1289.html" rel="external">"Pathogenesis and pathophysiology of bacterial meningitis"</a>)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>If possible, the pretreatment evaluation of children with suspected bacterial meningitis should include  (<a class="graphic graphic_table graphicRef74865" href="/z/d/graphic/74865.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Complete history and physical examination</p><p class="bulletIndent1"><span class="glyph">●</span>Blood tests (eg, complete blood count with differential, serum chemistries, coagulation studies, and inflammatory markers)</p><p class="bulletIndent1"><span class="glyph">●</span>Blood cultures</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrospinal fluid (CSF) studies (cell count and differential, glucose, protein)</p><p class="bulletIndent1"><span class="glyph">●</span>CSF Gram stain and culture</p><p></p><p>In cases in which the performance of a lumbar puncture (LP) is delayed by rapidly deteriorating clinical status or the need for neuroimaging, blood culture should be obtained before the administration of antibiotic therapy  (<a class="graphic graphic_table graphicRef74865" href="/z/d/graphic/74865.html" rel="external">table 1</a>).</p><p>The pretreatment evaluation of infants and children with suspected bacterial meningitis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">GENERAL MANAGEMENT</span></p><p class="headingAnchor" id="H3495668793"><span class="h2">Setting of care</span><span class="headingEndMark"> — </span>Children who are suspected of having bacterial meningitis based upon the results of the initial evaluation (including history, physical examination, laboratory tests, and cerebrospinal fluid [CSF] examination) should be admitted to the hospital for ongoing management. The level of inpatient care (ward versus pediatric intensive care unit) is determined by the severity of illness. Admission to a pediatric intensive care unit is appropriate for children with hemodynamic instability (ie, septic shock), significant respiratory compromise, prolonged or recurrent seizures, severely depressed mental status, rapidly deteriorating clinical status, or other potentially life-threatening complications.</p><p class="headingAnchor" id="H3222387414"><span class="h2">Supportive measures</span><span class="headingEndMark"> — </span>General supportive measures include:</p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate respiratory support for patients with hypoxia or labored breathing (see  <a class="medical medical_review" href="/z/d/html/6393.html" rel="external">"Initial assessment and stabilization of children with respiratory or circulatory compromise"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Establishing venous access (see  <a class="medical medical_review" href="/z/d/html/6385.html" rel="external">"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Appropriate hemodynamic support for children presenting with signs of shock (see  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of metabolic disturbances such as hypoglycemia, electrolyte abnormalities, and acidosis if present (see  <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/6100.html" rel="external">"Approach to the child with metabolic acidosis", section on 'Treatment'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of seizures if present (see  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Fluid management</span><span class="headingEndMark"> — </span>Careful management of fluid and electrolyte balance is an important aspect of supportive therapy. Both over- and underhydration are associated with adverse outcomes [<a href="#rid1">1</a>]. Hypotonic fluids (eg, one-half or one-quarter normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a>) should be <strong>avoided</strong> because they deliver too much free water, which contributes to hyponatremia and can exacerbate cerebral edema.</p><p>The approach to initial fluid management depends on hemodynamic stability, volume status, and whether there is evidence of syndrome of inappropriate secretion of antidiuretic hormone (SIADH; eg, serum sodium &lt;130 mEq/L):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shock</strong> – Children who are in shock should receive volume resuscitation with isotonic fluid to maintain blood pressure and cerebral perfusion. The management of septic shock in children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">"Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypovolemia without shock</strong> – Children who are volume depleted, but not in shock, should receive volume repletion with isotonic fluids with careful and frequent attention to fluid status. Daily weight, urine output, and serum electrolytes should be monitored. (See  <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SIADH</strong> – For children without signs of shock or hypovolemia who have evidence of SIADH (eg, serum sodium &lt;130 mEq/L), we suggest moderate fluid restriction (ie, two-thirds to three-quarters of maintenance). Daily weight, urine output, serum electrolytes, and, if indicated, serum and urine osmolalities should be carefully monitored. Fluid administration can be liberalized gradually once serum sodium is &gt;135 mEq/L. Most children can receive maintenance fluid intake within 24 to 48 hours of hospitalization. SIADH is common in children with bacterial meningitis. In one study, 10 percent of children with pneumococcal meningitis had initial serum sodium values &lt;130 mEq/L [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat", section on 'Fluid restriction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normovolemia without SIADH</strong> – Children without signs of shock, hypovolemia, or SIADH (eg, those with normal perfusion, normal serum sodium [≥135 mEq/L], and without signs of volume overload) can receive isotonic fluids at a maintenance rate (<a class="calc calc_professional" href="/z/d/html/13425.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/121761.html" rel="external">calculator 2</a>). However, fluid status and serum electrolytes should be reassessed regularly since SIADH can develop subsequent to the initial presentation. (See  <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">"Maintenance intravenous fluid therapy in children"</a>.)</p><p></p><p class="headingAnchor" id="H903646490"><span class="h2">Dexamethasone</span><span class="headingEndMark"> — </span>The role of <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> therapy to prevent hearing loss and other neurologic complications of bacterial meningitis in children is uncertain. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications", section on 'Dexamethasone'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Children who are being treated for bacterial meningitis should be monitored carefully for complications (eg, seizures, signs of elevated intracranial pressure, development of infected subdural effusions), particularly during the first two to three days of treatment when complications are most likely to occur [<a href="#rid3">3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Heart rate, blood pressure, and respiratory rate should be monitored regularly with a frequency appropriate to the care setting</p><p class="bulletIndent1"><span class="glyph">●</span>A complete neurologic examination should be performed daily; rapid assessment of neurologic function should be performed several times per day for the first several days of treatment</p><p></p><p class="headingAnchor" id="H1650480595"><span class="h2">Infection control</span><span class="headingEndMark"> — </span>All patients admitted to the hospital with meningitis should be placed on standard precautions [<a href="#rid4">4-6</a>]. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Standard precautions'</a>.)</p><p>In addition, droplet precautions are recommended for patients with suspected <em>Neisseria</em> <em>meningitidis </em>and <em>Haemophilus influenzae</em> type b (Hib) meningitis until they have received 24 hours of effective therapy [<a href="#rid4">4,5</a>]. Patients should be in private rooms, and hospital personnel should wear a face mask when they are within 3 feet (1 meter) of the patient.</p><p class="headingAnchor" id="H2791461832"><span class="h1">ANTIBIOTIC THERAPY</span></p><p class="headingAnchor" id="H2320219487"><span class="h2">Avoidance of delay</span><span class="headingEndMark"> — </span>Antibiotic therapy should be initiated immediately after lumbar puncture (LP) is performed if the clinical suspicion for meningitis is high  (<a class="graphic graphic_table graphicRef74865" href="/z/d/graphic/74865.html" rel="external">table 1</a>). Delay in the administration of appropriate antibiotics can have a deleterious effect on outcome for patients who are deteriorating rapidly.</p><p>If neuroimaging is to be performed before LP, antibiotic therapy should be initiated immediately after blood culture is obtained, before neuroimaging is performed. Although the administration of antimicrobial therapy before LP may affect the yield of cerebrospinal fluid (CSF) Gram stain and culture, pathogens other than meningococcus usually can be identified in the CSF up to several hours after the administration of antibiotics. (See  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Cerebrospinal fluid culture'</a>.)</p><p class="headingAnchor" id="H3944704962"><span class="h2">Treatment principles</span><span class="headingEndMark"> — </span>There are two general principles of antibiotic therapy for bacterial meningitis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bactericidal effect</strong> – Since the CSF is a site of impaired humoral immunity, a fundamental principle of therapy of bacterial meningitis is that antibiotics must achieve a bactericidal effect within CSF to result in optimal microbiologic cure [<a href="#rid7">7,8</a>]. This principle is supported by clinical observations of poor outcomes in patients receiving bacteriostatic therapy (eg, <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">clindamycin</a>, <a class="drug drug_pediatric" data-topicid="12830" href="/z/d/drug information/12830.html" rel="external">tetracycline</a>) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug entry into CSF</strong> – Treatment of bacterial meningitis requires adequate concentration of antibiotics in the CSF. Most drugs reach concentrations in the CSF that are only 10 to 20 percent of peak concentrations in the serum. This is because the blood-brain barrier blocks macromolecule entry into the CSF, with small, lipophilic molecules penetrating most easily.</p><p></p><p class="bulletIndent1">Inflammation increases the permeability of the blood-brain barrier, which can increase the peak concentration of drugs in the CSF. This was illustrated in one study that sequentially monitored CSF and serum penicillin levels in children with bacterial meningitis. The mean CSF:serum ratio two hours after administration of the same intravenous (IV) dose of penicillin was 42 percent on the first day of therapy but fell to less than 10 percent on the 10<sup>th</sup> day when the inflammatory changes had subsided [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/1285.html" rel="external">"Cerebrospinal fluid: Physiology and utility of an examination in disease states", section on 'Blood-brain barrier'</a>.)</p><p></p><p class="bulletIndent1">Because of the general limitation in antibiotic penetration into the CSF, all patients should be treated with parenteral antibiotics. Oral antibiotics are not appropriate for treatment of bacterial meningitis, since the dose and tissue levels tend to be considerably lower than with parenteral agents.</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Empiric therapy</span><span class="headingEndMark"> — </span>The organism causing bacterial meningitis seldom is known at the outset of therapy. As a result, the initial empiric treatment plan is based upon the most likely pathogens and local susceptibility patterns.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric regimen</strong> – The empiric regimen should include coverage for meningococcus and penicillin-resistant pneumococcus, the two most common causes of bacterial meningitis in infants and children. (See  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1">For most patients, we suggest the following regimen [<a href="#rid5">5,6</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">Vancomycin</a> 60 mg/kg/day IV (maximum dose 4 g/day) in four divided doses, <strong>plus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">Ceftriaxone</a> 100 mg/kg/day IV (maximum dose 4 g/day) in two divided doses, <strong>or</strong> <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> (where available) 300 mg/kg/day IV (maximum dose 12 g/day) in three or four divided doses</p><p></p><p class="bulletIndent1">We suggest twice-daily <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> dosing rather than once daily to avoid the possibility of inadequate treatment in the event of dosing errors, delayed doses, or missed doses [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">For children in whom cephalosporins or <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> are contraindicated (eg, severe allergy), consultation with a pediatric infectious diseases specialist is advised.</p><p></p><p class="bulletIndent1">Additional coverage may be warranted in the following circumstances  (<a class="graphic graphic_table graphicRef130047" href="/z/d/graphic/130047.html" rel="external">table 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immune deficiency, neurosurgery, or medical device – Children with immune deficiency, recent neurosurgery, penetrating head trauma, or anatomic defects may require additional empiric coverage, as summarized in the table  (<a class="graphic graphic_table graphicRef130047" href="/z/d/graphic/130047.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjunctive <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> – Some experts suggest the addition of <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a> to the empiric regimen if dexamethasone is administered [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications", section on 'Antibiotic regimen'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unusual pathogen on Gram stain – The CSF Gram stain may provide important clues for the need to broaden empiric therapy to cover for less common or unusual organisms. However, empiric antibiotics should not be narrowed based upon CSF Gram stain results, because Gram stain results are subject to observer misinterpretation [<a href="#rid11">11</a>]; broad-spectrum antimicrobial therapy should be continued until CSF culture results are available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of empiric therapy</strong> – The duration of empiric therapy depends upon the culture results, CSF parameters, and clinical concern for bacterial meningitis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Positive culture</strong> – Once culture results are available, treatment should be modified based on the specific pathogen isolated in CSF and/or blood culture. (See <a class="local">'Specific therapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Negative culture with normal CSF profile</strong> – For children who have a normal CSF profile and negative blood and CSF cultures, we usually discontinue antimicrobial therapy if cultures remain sterile after 48 to 72 hours of incubation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Negative culture with CSF pleocytosis</strong> – For children with CSF pleocytosis whose blood and CSF cultures remain negative after 48 to 72 hours, the decision to continue or discontinue empiric antibiotic therapy is individualized based upon the clinical status of the child and level of clinical concern for bacterial meningitis. Consultation with a pediatric infectious diseases specialist is advised if the clinician is uncertain how to manage such children. Important considerations include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>CSF cultures may be negative in children who received antibiotic therapy before CSF examination (see  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Cerebrospinal fluid culture'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Negative CSF culture does not preclude the development of meningitis hours or days after the LP; if clinical signs suggest meningitis, repeat LP may be warranted</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Molecular tests can help to identify the specific pathogen in some cases (see  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Molecular methods'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Nonbacterial causes of CSF pleocytosis should also be considered (see  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5983.html" rel="external">"Viral meningitis in children: Clinical features and diagnosis", section on 'Distinguishing viral from bacterial meningitis'</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h2">Specific therapy</span><span class="headingEndMark"> — </span>Once the causative agent and its in vitro antimicrobial susceptibility pattern are known, empiric antimicrobial therapy can be altered accordingly. The following sections discuss the choice of antimicrobial regimen according to the isolated pathogen. Guidance on treatment duration is provided below. (See <a class="local">'Treatment duration'</a> below.)</p><p class="headingAnchor" id="H2471077773"><span class="h3">Streptococcus pneumoniae</span><span class="headingEndMark"> — </span>The therapeutic options for pneumococcal meningitis are summarized in the table  (<a class="graphic graphic_table graphicRef79959" href="/z/d/graphic/79959.html" rel="external">table 3</a>) and discussed in the following sections [<a href="#rid6">6</a>]. The increasing prevalence of antibiotic-resistant <em>S. pneumoniae</em> has important implications for the treatment of pneumococcal meningitis, as discussed below. (See  <a class="medical medical_review" href="/z/d/html/7034.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to beta-lactam antibiotics"</a> and  <a class="medical medical_review" href="/z/d/html/7023.html" rel="external">"<i>Streptococcus pneumoniae</i>: Microbiology and pathogenesis of infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Penicillin-susceptible isolates</strong> – In children with penicillin-susceptible isolates (minimum inhibitory concentration [MIC] ≤0.06 mcg/mL), treatment consists of [<a href="#rid6">6</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12687" href="/z/d/drug information/12687.html" rel="external">Penicillin G</a> 300,000 units/kg/day intravenously (IV) in four to six divided doses, <strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-dose <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> or <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> (ie, same dose as for empiric therapy)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Penicillin-nonsusceptible, cephalosporin-susceptible isolates</strong> – In children with isolates that are penicillin-nonsusceptible (intermediate or resistant; MIC &gt;0.06 mcg/mL) but susceptible to <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> and <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> (MIC ≤0.5 mcg/mL), treatment consists of high-dose ceftriaxone or cefotaxime [<a href="#rid6">6</a>]. Ceftriaxone and cefotaxime can attain levels of only 3 to 8 mcg/mL in the CSF and achieve reliable bactericidal activity only if the MIC is ≤0.5 mcg/mL [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cephalosporin-nonsusceptible isolates</strong> – In children with isolates nonsusceptible to <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> and <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> (intermediate [MIC = 1 mcg/mL] or resistant [MIC ≥2 mcg/mL]), treatment consists of:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">Vancomycin</a> 60 mg/kg/day IV (maximum dose 4 g/day) in four divided doses, <strong>plus</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-dose <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> or <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">Rifampin</a> (20 mg/kg/day IV in two divided doses) may be added in selected circumstances (as described below)</p><p></p><p class="bulletIndent1">Treatment with extended-spectrum cephalosporins alone is generally not sufficient for isolates with intermediate susceptibility to <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> or <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> (MIC = 1 mcg/mL) [<a href="#rid6">6</a>]. In the context of central nervous system infections, isolates with MICs ≥2 mcg/mL are considered resistant  (<a class="graphic graphic_table graphicRef63881" href="/z/d/graphic/63881.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">Rifampin</a> may be added to the regimen (if the isolate is susceptible) in the following settings [<a href="#rid6">6</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the isolate has a high MIC for cephalosporins (≥4 mcg/mL)</p><p class="bulletIndent2"><span class="glyph">•</span>If the patient appears to be failing <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a></p><p class="bulletIndent2"><span class="glyph">•</span>If repeat cerebrospinal fluid culture is not sterile (see <a class="local">'Repeat lumbar puncture'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>If the patient was treated with <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other antimicrobials</strong> – Other antibiotics that are rarely used in the treatment of resistant pneumococcal meningitis include <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a> and respiratory fluoroquinolones (eg, <a class="drug drug_pediatric" data-topicid="114796" href="/z/d/drug information/114796.html" rel="external">moxifloxacin</a>, <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="8760" href="/z/d/drug information/8760.html" rel="external">gemifloxacin</a>) [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">Meropenem</a> is effective in vitro but should not be used for monotherapy [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1">Fluoroquinolones are not routinely recommended for use in children due to the potential risk of musculoskeletal toxicity. However, for serious infections such as meningitis, it is reasonable to use a systemic fluoroquinolone when no safe or effective alternative exists. (See  <a class="medical medical_review" href="/z/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Children'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13145" href="/z/d/drug information/13145.html" rel="external">Chloramphenicol</a> also has been used for patients with an allergy to penicillin and cephalosporin. Unfortunately, many penicillin-resistant strains are somewhat resistant to chloramphenicol killing (despite in vitro tests that show inhibition) and treatment failures of meningitis caused by penicillin-resistant <em>S. pneumoniae</em> have occurred when chloramphenicol was used [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H1160503407"><span class="h3">Neisseria meningitidis</span><span class="headingEndMark"> — </span>The preferred agents for meningococcal meningitis are third-generation cephalosporins (eg, <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> 100 mg/kg/day IV in two divided doses [maximum 4 g/day] or <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> [where available] 225 to 300 mg/kg/day IV [maximum dose 12 g/day] in three or four divided doses). High-dose <a class="drug drug_pediatric" data-topicid="12687" href="/z/d/drug information/12687.html" rel="external">penicillin G</a> (300,000 units/kg/day in four divided doses) is an alternative low-cost option. However, the susceptibility of the isolate to penicillin should be documented before switching to penicillin since beta-lactamase-producing <em>N. meningitidis </em>isolates have been reported [<a href="#rid15">15,16</a>]. Patients treated with penicillin should receive antimicrobial chemoprophylaxis to eradicate nasopharyngeal carriage prior to discharge. Treatment of meningococcal meningitis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Antibiotic therapy'</a>.)</p><p class="headingAnchor" id="H3939155985"><span class="h3">Haemophilus influenzae</span><span class="headingEndMark"> — </span>Meningitis due to <em>H. influenzae</em> is usually treated with a third-generation cephalosporin such as <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> (100 mg/kg/day IV in two divided doses [maximum dose 4 g/day]) or <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> (where available; 200 mg/kg/day IV in three or four divided doses [maximum dose 12 g/day]). <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">Ampicillin</a> is appropriate only if the infecting pathogen has been shown to be beta-lactamase negative. Patients with meningitis due to <em>H. influenzae</em> type b who are treated with agents other than ceftriaxone or cefotaxime should receive antibiotic chemoprophylaxis prior to discharge [<a href="#rid17">17</a>]. Treatment of <em>H. influenzae</em> meningitis and postexposure chemoprophylaxis are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/8048.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of <i>Haemophilus influenzae</i>", section on 'Directed treatment'</a> and  <a class="medical medical_review" href="/z/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection", section on 'Postexposure chemoprophylaxis'</a>.)</p><p class="headingAnchor" id="H2863386169"><span class="h3">Listeria monocytogenes</span><span class="headingEndMark"> — </span>The preferred regimen for treatment of meningitis due to <em>L. monocytogenes</em> in infants and children consists of <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> (300 mg/kg/day IV in four divided doses [maximum dose 12 g/day]) <strong>plus</strong> <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> (7.5 mg/kg/day IV in three divided doses)  (<a class="graphic graphic_table graphicRef122593" href="/z/d/graphic/122593.html" rel="external">table 5</a>). The usual treatment duration is 21 to 28 days (gentamicin may not need to be continued for the entire duration). (See  <a class="medical medical_review" href="/z/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection", section on 'Preferred regimen'</a>.)</p><p class="headingAnchor" id="H81497811"><span class="h3">Group B streptococcus (GBS)</span><span class="headingEndMark"> — </span>The preferred agents for treatment of GBS (<em>Streptococcus agalactiae</em>) meningitis are <a class="drug drug_pediatric" data-topicid="12687" href="/z/d/drug information/12687.html" rel="external">penicillin G</a> (450,000 to 500,000 units/kg/day IV in four divided doses) <strong>or</strong> <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a> (300 mg/kg/day IV in three divided doses). The usual treatment duration is 14 to 21 days. Treatment of GBS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5961.html" rel="external">"Group B streptococcal infection in neonates and young infants", section on 'Definitive therapy'</a>.)</p><p class="headingAnchor" id="H2296171126"><span class="h3">Staphylococcus aureus</span><span class="headingEndMark"> — </span>Meningitis caused by <em>S. aureus</em> is uncommon in children unless there is an underlying anatomic defect (eg, dermal sinus), immune dysfunction, or implanted device (eg, CSF drain or shunt). Management of CSF shunt infections is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1286.html" rel="external">"Infections of cerebrospinal fluid shunts", section on 'Treatment'</a>.)</p><p>Antimicrobial therapy for <em>S. aureus</em> meningitis is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MSSA</strong> – The standard therapy for methicillin-susceptible <em>S. aureus</em> (MSSA) meningitis is <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">nafcillin</a> or <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">oxacillin</a> (both are dosed at 150 to 200 mg/kg/day IV in four doses [maximum 12 g/day]) [<a href="#rid11">11,18</a>]. Treatment duration is typically 14 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRSA</strong> – The preferred therapy for methicillin-resistant <em>S. aureus</em> (MRSA) meningitis is <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> (60 mg/kg/day IV in four divided doses [maximum dose 4 g/day]) [<a href="#rid11">11,18,19</a>]. Treatment duration is at least 14 days. Some experts recommend adding <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a> to vancomycin if the isolate is susceptible to rifampin (20 mg/kg/day orally or IV in two divided doses [maximum dose 600 mg/day]).</p><p></p><p class="bulletIndent1">Alternative agents for MRSA meningitis include <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">ceftaroline</a> (45 mg/kg/day in three divided doses), <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX; 10 to 12 mg/kg of the TMP component and 50 to 60 mg/kg of the SMX component per day in four divided doses) or <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a> (in patients &lt;12 years old: 30 mg/kg/day IV in three divided doses [maximum dose 1200 mg/day]; in patients ≥12 years old: 600 mg IV twice per day) [<a href="#rid11">11,18,19</a>]:</p><p></p><p class="bulletIndent1">Inflammation of the meninges does not appear to affect penetration of <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">linezolid</a> into the CSF [<a href="#rid20">20-23</a>]. Rapid penetration has been demonstrated in children and adolescents [<a href="#rid23">23</a>]. However, CSF concentrations are variable and correlation of CSF and plasma levels is inconsistent. Furthermore, linezolid is not bactericidal, but some case reports document successful linezolid treatment of staphylococcal meningitis [<a href="#rid18">18,24</a>].</p><p></p><p>Treatment of invasive MSSA and MRSA infections in children is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections", section on 'Definitive antimicrobial therapy'</a>.)</p><p class="headingAnchor" id="H2456360908"><span class="h3">Gram-negative rods (GNRs)</span><span class="headingEndMark"> — </span>Consultation with a pediatric infectious diseases specialist is advised for children with meningitis caused by a GNR. Choices for IV therapy are outlined here and discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1286.html" rel="external">"Infections of cerebrospinal fluid shunts"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enteric GNR</strong> – The usual treatment regimen for susceptible isolates consists of an extended-spectrum cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> 100 mg/kg/day IV in two divided doses [maximum dose 4 g/day] <strong>or</strong> <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a> [where available] 200 to 300 mg/kg/day IV in four divided doses [maximum dose 12 g/day]) <strong>plus</strong> an aminoglycoside (eg, <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">gentamicin</a> 7.5 mg/kg/day IV in three divided doses) [<a href="#rid25">25</a>]. The aminoglycoside often can be discontinued after the first five to seven days, once the CSF is documented to be sterile.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Pseudomonas</em></strong><strong> </strong><strong><em>aeruginosa</em></strong> – <a class="drug drug_pediatric" data-topicid="13134" href="/z/d/drug information/13134.html" rel="external">Ceftazidime</a> (150 mg/kg/day IV in three divided doses [maximum dose 6 g/day]) or <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">cefepime</a> (150 mg/kg/day IV in three divided doses [maximum dose 6 g/day]) are the most effective cephalosporins for treating susceptible <em>P. aeruginosa</em> infections [<a href="#rid26">26</a>]. For ceftazidime-resistant strains, <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">meropenem</a> (120 mg/kg/day IV in three divided doses [maximum dose 6 g/day]) is an effective treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extended-spectrum beta-lactamase (ESBL)-producing organisms</strong> – <a class="drug drug_pediatric" data-topicid="12583" href="/z/d/drug information/12583.html" rel="external">Meropenem</a> (120 mg/kg/day IV in three divided doses [maximum dose 6 g/day]) is the agent of choice in the treatment of meningitis caused by susceptible ESBL-producing GNRs [<a href="#rid27">27,28</a>].</p><p></p><p>Repeat LP should be performed two to three days after starting therapy to assess the efficacy of treatment. (See <a class="local">'Repeat lumbar puncture'</a> below.)</p><p class="bulletIndent2">Occasionally, IV therapy alone is insufficient and intraventricular administration of an antibiotic (typically an aminoglycoside) is necessary to sterilize the CSF. Intraventricular therapy should be undertaken in consultation with specialists in pediatric infectious diseases and neurosurgery. This issue is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1286.html" rel="external">"Infections of cerebrospinal fluid shunts", section on 'Adjunctive intraventricular antibiotics in selected cases'</a>.)</p><p></p><p class="headingAnchor" id="H32"><span class="h2">Treatment duration</span><span class="headingEndMark"> — </span>The duration of antimicrobial therapy depends upon the causative organism and clinical course. We suggest the following durations of therapy for uncomplicated meningitis caused by the following organisms [<a href="#rid4">4-6,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>S. pneumoniae</em> – 10 to 14 days</p><p class="bulletIndent1"><span class="glyph">●</span><em>N. meningitidis</em> – 5 to 7 days</p><p class="bulletIndent1"><span class="glyph">●</span><em>H. influenzae</em> – 7 to 10 days</p><p class="bulletIndent1"><span class="glyph">●</span><em>L. monocytogenes</em> – 21 to 28 days</p><p class="bulletIndent1"><span class="glyph">●</span><em>S. aureus</em> – At least two weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Gram-negative bacilli – Three weeks or a minimum of two weeks beyond the first sterile CSF culture, whichever is longer</p><p></p><p>Limited observational and clinical trial data suggest that in carefully selected cases, a shorter duration of therapy may be equally efficacious and may reduce hospital duration and health care costs [<a href="#rid29">29-31</a>]. However, due to the limitations of these data, as described below, we view the findings as preliminary and continue to suggest organism-specific durations of therapy, as outlined above.</p><p>A 2009 meta-analysis of five randomized trials (383 children) found that treatment for 4 to 7 days resulted in rates of cure similar to treatment for 7 to 14 days (odds ratio 1.24, 95% CI 0.73-2.11) [<a href="#rid30">30</a>]. However, the trials included in the meta-analysis had important limitations, including lack of blinding in all five trials, small number of patients, and relatively short follow-up. In addition, there was considerable variability in the distribution of causative organisms in the different trials, with the most common being <em>S. pneumoniae</em>, <em>N. meningitidis</em>, and <em>H</em>. <em>influenzae</em> type b (Hib). In a subsequent multicenter trial in resource-limited countries involving &gt;1000 children with bacterial meningitis (<em>S. pneumoniae </em>in 33 percent, Hib in 26 percent, <em>N. meningitidis</em> in 7 percent, and no identified cause in 33 percent), outcomes were generally similar among children treated with <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a> for 5 versus 10 days [<a href="#rid29">29</a>]. There were two cases of relapse in the 5-day group versus none in the 10-day group, and there were nine meningitis-related deaths (2 percent) in the 5-day group versus six (1 percent) in the 10-day group. While these differences were not statistically significant, the study may have been underpowered to detect important differences. Furthermore, the setting, methodology, and lack of organism-specific outcome information preclude generalizability to resource-abundant settings [<a href="#rid29">29,32</a>].</p><p class="headingAnchor" id="H34"><span class="h2">Outpatient therapy</span><span class="headingEndMark"> — </span>In selected patients, a portion of parenteral antibiotic therapy may be administered in the outpatient setting [<a href="#rid11">11,33</a>]. In our practice, we very rarely complete antimicrobial therapy for bacterial meningitis at home; however, it may be a reasonable option for some patients if <strong>all</strong> of the following criteria are met [<a href="#rid34">34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient is clinically stable and afebrile for at least 24 to 48 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient has completed at least six days of inpatient therapy – Serious adverse complications of meningitis are uncommon after three or four days of therapy, particularly in children who are clinically well and afebrile [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient has normal or nearly normal neurologic function (no focal findings and no seizure activity).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no concern for complications of meningitis on neuroimaging (eg, no abscess or subdural collection).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient is able to take fluids by mouth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient has reliable venous access (ie, a peripherally inserted central catheter or tunneled central venous catheter).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caregivers are reliable and have transportation and a telephone.</p><p></p><p>If the outpatient regimen will be different from the regimen given in the hospital, we suggest that the first dose be supervised in the hospital to ensure that the patient tolerates it. Home antibiotic therapy should be administered by a qualified home health nursing professional or a caregiver who has received proper instruction. If the family is not comfortable administering the antibiotics, arrangements can be made to administer antibiotics in the office. In addition, the patient should be examined daily by a clinician (eg, visiting nurse, primary care provider). If any concerns arise (recurrence of fever, new neurologic findings), the patient should be referred for further evaluation.</p><p>Potential advantages of completing therapy in the outpatient setting are that it decreases the risk of nosocomial infection, improves quality of life for the patient and family, and decreases health care costs [<a href="#rid34">34,36</a>]. Risks include the potential for missed doses, administration errors, catheter-related complications, adverse drug events, and risks posed by provision of care by caregivers who may lack formal medical training. Careful patient selection and close monitoring are keys to the success and safety of this approach [<a href="#rid34">34,36,37</a>].</p><p>Additional details regarding outpatient parenteral antibiotic therapy are provided separately. (See  <a class="medical medical_review" href="/z/d/html/117307.html" rel="external">"Outpatient parenteral antimicrobial therapy"</a>.)</p><p class="headingAnchor" id="H36"><span class="h1">RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>The response to therapy is monitored with clinical and laboratory parameters (eg, fever curve, resolution of symptoms and signs, normalization of inflammatory markers) and by neuroimaging.</p><p class="headingAnchor" id="H37"><span class="h2">Duration of fever</span><span class="headingEndMark"> — </span>Fevers typically last three to six days after initiating adequate therapy [<a href="#rid3">3</a>]. Fever lasts &gt;5 days in approximately 10 to 15 percent of patients [<a href="#rid3">3,38</a>]; secondary fever (eg, recurrence of fever after being afebrile for at least 24 hours) occurs in approximately 15 to 20 percent [<a href="#rid3">3,38</a>].</p><p>Causes of persistent or secondary fever include [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate treatment</p><p class="bulletIndent1"><span class="glyph">●</span>Development of nosocomial infection (eg, infected intravenous [IV] catheters, urinary tract infection, viral infection); nosocomial infection is more often associated with secondary fever than with persistent fever</p><p class="bulletIndent1"><span class="glyph">●</span>Discontinuation of <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> (see  <a class="medical medical_review" href="/z/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications", section on 'Adverse effects'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Development of a suppurative complication (pericarditis, pneumonia, arthritis, subdural empyema  (<a class="graphic graphic_diagnosticimage graphicRef117506" href="/z/d/graphic/117506.html" rel="external">image 1</a> and <a class="graphic graphic_picture graphicRef117505" href="/z/d/graphic/117505.html" rel="external">picture 1</a>))</p><p class="bulletIndent1"><span class="glyph">●</span>Drug fever (a diagnosis of exclusion)</p><p></p><p>In patients with persistent or secondary fever, suppurative and nosocomial complications should be carefully sought. The evaluation typically includes repeat blood culture, complete blood count, C-reactive protein, and urinalysis. The need for repeat evaluation of the cerebrospinal fluid (CSF) should be considered on an individual basis. In many cases, a specific cause of prolonged fever cannot be determined. In the patient who is improving daily but has unexplained fever despite careful evaluation, it is thought that the individual's host response to infection is responsible for the prolonged fever.</p><p class="headingAnchor" id="H2117485903"><span class="h2">Repeat blood culture</span><span class="headingEndMark"> — </span>As discussed above, repeat blood culture may be warranted in patients with persistent or secondary fever. In addition, for patients who had a positive blood culture at initial evaluation, blood culture should be repeated to document sterility of the blood stream. The follow-up blood culture is usually obtained when it is known that the initial blood culture is positive.</p><p class="headingAnchor" id="H38"><span class="h2">Repeat lumbar puncture</span><span class="headingEndMark"> — </span>Reexamination of the CSF is warranted in the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>Poor clinical response – Patients who have a poor clinical response despite 24 to 36 hours of appropriate antimicrobial therapy should undergo repeat lumbar puncture (LP) [<a href="#rid11">11</a>]. This is particularly important in the following settings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children with cephalosporin-resistant pneumococcal meningitis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children with high bacterial burden in CSF (eg, sheets of bacteria on Gram stain)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children with pneumococcal meningitis who were treated with <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> (since dexamethasone may interfere with the ability of the clinician to assess clinical response such as resolution of fever) (see  <a class="medical medical_review" href="/z/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications", section on 'Adverse effects'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gram-negative bacillary meningitis – Patients with gram-negative bacillary meningitis should undergo repeat LP two to three days after beginning treatment to document that the CSF is sterile and to determine treatment duration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent or recurrent fever – Repeat LP also may be indicated in children with persistent or recurrent fever. The decision to perform repeat LP in this setting is individualized, as discussed above. (See <a class="local">'Duration of fever'</a> above.)</p><p></p><p>Reexamination of the CSF in these settings informs decisions about extending duration of therapy and/or changing the antibiotic regimen. Extension of the duration of therapy is indicated if <strong>any</strong> of the following are noted:</p><p class="bulletIndent1"><span class="glyph">●</span>CSF cultures from the repeat LP grow a pathogenic organism</p><p class="bulletIndent1"><span class="glyph">●</span>CSF examination at the conclusion of the standard treatment duration shows &gt;30 percent neutrophils</p><p class="bulletIndent1"><span class="glyph">●</span>CSF examination at the conclusion of the standard treatment duration shows CSF glucose of &lt;20 mg/dL (or &lt;20 percent of the blood glucose level)</p><p></p><p class="headingAnchor" id="H39"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Neuroimaging (with computed tomography or magnetic resonance imaging) may be indicated during the course of treatment to assess for complications such as subdural empyema, brain abscess, cerebral vascular thrombosis, or hydrocephalus. Indications for neuroimaging may include [<a href="#rid39">39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Focal neurologic signs or prolonged obtundation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained persistent fever</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing head circumference in young infants</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures occurring &gt;72 hours after the start of treatment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistently positive CSF cultures despite appropriate antibiotic therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persistent elevation of CSF neutrophils (&gt;30 to 40 percent) at the completion of standard duration of therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gram-negative meningitis in young infants – Neuroimaging is usually performed sometime during treatment to evaluate for hydrocephalus and other complications of the meningitis (see  <a class="medical medical_review" href="/z/d/html/6000.html" rel="external">"Bacterial meningitis in children: Neurologic complications"</a> and  <a class="medical medical_review" href="/z/d/html/110031.html" rel="external">"Hydrocephalus in children: Clinical features and diagnosis", section on 'Neuroimaging'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meningitis caused by the organism with a propensity to cause abscess (eg, <em>Citrobacter</em>, <em>Cronobacter</em>, <em>Streptococcus</em> <em>anginosus</em>)</p><p></p><p>In addition, imaging is warranted in children who experience recurrent meningitis to evaluate the possibility of a communication between the nasal passage or ear and the meninges [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H40"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H41"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Reported mortality rates among children with bacterial meningitis range from 0 to 15 percent, depending upon the setting, era, and infecting organism [<a href="#rid41">41-47</a>]. In resource-abundant settings, mortality rates associated with bacterial meningitis are approximately 4 to 5 percent [<a href="#rid44">44,45</a>]. Reported mortality rates in resource-limited countries are approximately 8 to 10 percent [<a href="#rid44">44</a>].</p><p>Case-fatality rates according to the organism isolated are as follows [<a href="#rid2">2,41,42,44,48,49</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><em>H. influenzae</em> type b (Hib) – 4 to 5 percent </p><p class="bulletIndent1"><span class="glyph">●</span><em>N. meningitidis</em> – 7 percent</p><p class="bulletIndent1"><span class="glyph">●</span><em>S. pneumoniae</em> – 7 to 15 percent </p><p></p><p>The risk of mortality is increased in children who are comatose or in shock at the time of admission and in those who require mechanical ventilation [<a href="#rid42">42,50,51</a>]. </p><p class="headingAnchor" id="H42"><span class="h2">Neurologic sequelae</span><span class="headingEndMark"> — </span>Persistent neurologic sequelae are common in children who survive an episode of bacterial meningitis. The most common sequelae include hearing loss, seizures, intellectual disability, and spasticity and/or paresis. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6000.html" rel="external">"Bacterial meningitis in children: Neurologic complications"</a>.)</p><p class="headingAnchor" id="H43"><span class="h2">Prognostic factors</span><span class="headingEndMark"> — </span>Factors related to the outcome of bacterial meningitis in children include [<a href="#rid42">42,52-58</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Level of consciousness at the time of admission</strong> – In an analysis of data from 654 children with bacterial meningitis, the Glasgow Coma Score (GCS)  (<a class="graphic graphic_table graphicRef59662" href="/z/d/graphic/59662.html" rel="external">table 6</a>) at admission was the strongest independent predictor of death or severe neurologic sequelae at the time of hospital discharge [<a href="#rid53">53</a>]. The likelihood of death from severe neurologic disability increased with decreasing GCS (approximately 10-fold higher risk with GCS 7 to 9 and approximately 30-fold higher risk with GCS ≤6).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiologic agent</strong> – The risk of death or neurologic sequelae is higher in children with pneumococcal meningitis than with meningococcal or Hib meningitis [<a href="#rid42">42,50</a>]. </p><p></p><p class="bulletIndent1">The risk of hearing impairment is also related to etiologic agent. Hearing loss occurs in approximately 31 percent of children with pneumococcal meningitis, 11 percent of children with meningococcal meningitis, and 6 percent of children with Hib meningitis [<a href="#rid42">42,56,59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizures</strong> – In a multicenter pneumococcal meningitis surveillance study, the occurrence of seizures more than 72 hours after initiation of appropriate antimicrobial therapy was associated with increased risk of neurologic sequelae [<a href="#rid42">42</a>]. In a series of children with Hib meningitis, seizures were associated with subtle cognitive and learning problems [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cerebrospinal fluid (CSF) glucose concentration</strong> – Decreased CSF glucose concentration (&lt;20 mg/dL [1.1 mmol/L]) at the time of admission appears to be associated with increased risk of hearing loss [<a href="#rid42">42,54,55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed sterilization of the CSF</strong> – Delayed sterilization of the CSF (persistently positive culture 16 to 18 hours after the initiation of therapy) is associated with adverse outcomes, including moderate to profound sensorineural hearing loss, seizures, hemiparesis, and abnormal neurologic findings at the time of discharge [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Underlying conditions</strong> – Children with underlying immunodeficiency, malnutrition, malignancy, or preexisting neurologic disease have a higher risk of death or neurologic sequelae [<a href="#rid57">57,58</a>].</p><p></p><p class="headingAnchor" id="H44"><span class="h1">FOLLOW-UP</span></p><p class="headingAnchor" id="H45"><span class="h2">Hearing evaluation</span><span class="headingEndMark"> — </span>Hearing evaluation should be performed at the time of or shortly after discharge from the hospital [<a href="#rid62">62,63</a>]. Hearing may be assessed by pure tone audiometry; auditory brainstem response may be used in young children or those who cannot cooperate with pure tone audiometry. Hearing evaluation should be repeated if the results of the initial evaluation suggest more than a minor hearing loss. (See  <a class="medical medical_review" href="/z/d/html/6297.html" rel="external">"Hearing loss in children: Screening and evaluation"</a>.)</p><p class="headingAnchor" id="H46"><span class="h2">Developmental screening</span><span class="headingEndMark"> — </span>Young children who have been treated for meningitis are at risk for developmental delay. Developmental surveillance should continue throughout childhood. (See  <a class="medical medical_review" href="/z/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care"</a>.)</p><p class="headingAnchor" id="H3448643646"><span class="h2">Evaluation for immunodeficiency</span><span class="headingEndMark"> — </span>Children who develop pneumococcal meningitis with a vaccine serotype  (<a class="graphic graphic_table graphicRef77274" href="/z/d/graphic/77274.html" rel="external">table 7</a>) despite having received at least one dose of pneumococcal conjugate vaccine and those who develop <em>Haemophilus influenzae</em> type b (Hib) meningitis despite two or more doses of the Hib vaccine may have an underlying immunodeficiency. In such cases, an evaluation of the child’s immune status with serum immunoglobulin levels and human immunodeficiency virus (HIV) testing can be considered [<a href="#rid6">6,64</a>]. Infections caused by pneumococcal serotype 3 are an exception to this since pneumococcal conjugate vaccines are less protective against this serotype. </p><p>In one study of 163 children who underwent immune evaluation after being diagnosed with invasive pneumococcal disease (87 percent had meningitis), 10 percent were found to have an underlying primary immunodeficiency [<a href="#rid64">64</a>]. However, in another study that included 28 children who underwent immune evaluation because they developed invasive pneumococcal disease despite receiving ≥2 doses of pneumococcal conjugate vaccine, only one child was found to have an immunodeficiency [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H47"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H49"><span class="h2">Chemoprophylaxis</span><span class="headingEndMark"> — </span>Chemoprophylaxis in the following clinical settings is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span><em>N. meningitidis</em> – Chemoprophylaxis is indicated in close contacts of patients with meningococcal meningitis  (<a class="graphic graphic_table graphicRef51944" href="/z/d/graphic/51944.html" rel="external">table 8</a>). This is discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Antimicrobial chemoprophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>H</em>. <em>influenzae</em> type b (Hib) – Chemoprophylaxis may be indicated for certain close contacts of a child with Hib meningitis, depending upon individual circumstances. This is discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection", section on 'Postexposure chemoprophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>S. pneumoniae</em> – Although it does not have a role in preventing the spread of pneumococcal meningitis, chemoprophylaxis is an important aspect of prevention of invasive pneumococcal infections in children with functional or anatomic asplenia. (See  <a class="medical medical_review" href="/z/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Infection prevention'</a> and  <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Antibiotic prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Basilar skull fractures – Basilar skull fractures with underlying dural tears are associated with cerebrospinal fluid (CSF) leaks and predispose patients to meningitis because of the potential for direct communication of bacteria in the upper respiratory tract with the central nervous system. The available evidence does <strong>not</strong> support the routine use of antibiotics prophylactically to prevent meningitis in this setting [<a href="#rid66">66</a>]. Furthermore, the majority of CSF leaks resolve spontaneously within one week of injury. However, the incidence of bacterial meningitis rises substantially if a leak persists past seven days and prophylactic antibiotics may be appropriate in some cases, particularly if the leak cannot be repaired in a timely manner. (See  <a class="medical medical_review" href="/z/d/html/6563.html" rel="external">"Skull fractures in children: Clinical manifestations, diagnosis, and management", section on 'Basilar skull fractures'</a>.)</p><p></p><p class="headingAnchor" id="H50"><span class="h2">Vaccines</span><span class="headingEndMark"> — </span>Vaccines directed against each of the major pathogens causing bacterial meningitis in children are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span><em>S. pneumoniae</em> (see  <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">"Pneumococcal vaccination in children"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span><em>N. meningitidis</em> (see  <a class="medical medical_review" href="/z/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Hib (see  <a class="medical medical_review" href="/z/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection"</a>)</p><p></p><p class="headingAnchor" id="H117417296"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110423.html" rel="external">"Society guideline links: Bacterial meningitis in infants and children"</a>.)</p><p class="headingAnchor" id="H15506832"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15649.html" rel="external">"Patient education: Meningitis in children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16956.html" rel="external">"Patient education: Bacterial meningitis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1187.html" rel="external">"Patient education: Meningitis in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H51"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General supportive management</strong> – Children with suspected bacterial meningitis should be admitted to the hospital for ongoing management. Supportive management of children with bacterial meningitis includes  (<a class="graphic graphic_table graphicRef74865" href="/z/d/graphic/74865.html" rel="external">table 1</a>) (see <a class="local">'General management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Appropriate respiratory and hemodynamic support for patients with respiratory compromise or shock (see  <a class="medical medical_review" href="/z/d/html/6393.html" rel="external">"Initial assessment and stabilization of children with respiratory or circulatory compromise"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Careful management of fluid and electrolyte balance (see <a class="local">'Fluid management'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitoring for complications (eg, seizures, signs of elevated intracranial pressure, development of infected subdural effusions) (see <a class="local">'Monitoring'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Expert opinion differs on the use of <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> in children with suspected meningitis; this issue is discussed separately (see  <a class="medical medical_review" href="/z/d/html/6026.html" rel="external">"Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologic complications"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antibiotic therapy</strong> – For most patients older than one month with suspected meningitis, we suggest <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">vancomycin</a> <strong>plus</strong> high doses of a third-generation cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">ceftriaxone</a>, <a class="drug drug_pediatric" data-topicid="13129" href="/z/d/drug information/13129.html" rel="external">cefotaxime</a>) rather than other regimens (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This combination provides coverage for antibiotic-resistant <em>Streptococcus pneumoniae,</em> <em>Neisseria meningitidis,</em> and <em>Haemophilus influenzae </em>(type b [Hib] and non-type b), which are the most common causes of bacterial meningitis in children. Additional coverage may be warranted in select circumstances, as summarized in the table  (<a class="graphic graphic_table graphicRef130047" href="/z/d/graphic/130047.html" rel="external">table 2</a>). Empiric antibiotic therapy should be initiated immediately after lumbar puncture (LP) is performed if the clinical suspicion for meningitis is high  (<a class="graphic graphic_table graphicRef74865" href="/z/d/graphic/74865.html" rel="external">table 1</a>). (See <a class="local">'Empiric therapy'</a> above and <a class="local">'Avoidance of delay'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific therapy</strong> – Once the causative agent and its in vitro antimicrobial susceptibility pattern are known, empiric antimicrobial therapy can be altered accordingly. The duration of antimicrobial therapy depends upon the causative organism and the clinical course. (See <a class="local">'Specific therapy'</a> above and <a class="local">'Treatment duration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response to therapy</strong> – The response to therapy is monitored with clinical and laboratory parameters (eg, fever curve, resolution of symptoms and signs, normalization of inflammatory markers). Fevers typically last three to six days after initiating adequate therapy. Repeat LP and/or neuroimaging may be warranted in some patients (see <a class="local">'Response to therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Repeat LP</strong> – Reexamination of cerebrospinal fluid (CSF) is indicated for patients with gram-negative bacillary meningitis (to document that the CSF is sterile) and in patients who have a poor clinical response despite 24 to 36 hours of appropriate antimicrobial therapy. Repeat LP also may be warranted in patients with persistent or recurrent fever. (See <a class="local">'Repeat lumbar puncture'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neuroimaging</strong> – Neuroimaging may be indicated during the course of treatment to assess for complications such as subdural empyema, brain abscess, cerebral vascular thrombosis, or hydrocephalus. Indications for neuroimaging may include focal neurologic signs, prolonged obtundation, increasing head circumference, seizures occurring &gt;72 hours after the start of treatment, persistently positive CSF cultures, or persistent CSF neutrophilia despite appropriate antibiotic therapy. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The mortality rate for children with bacterial meningitis in resource-abundant settings is approximately 4 to 5 percent. Neurologic complications are common among survivors. The most common sequelae include hearing loss, seizures, intellectual disability, and spasticity and/or paresis. (See <a class="local">'Prognosis'</a> above and  <a class="medical medical_review" href="/z/d/html/6000.html" rel="external">"Bacterial meningitis in children: Neurologic complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – Children who have been treated for bacterial meningitis should undergo hearing evaluation at the time of or shortly after discharge. They should also be followed closely for other neurologic sequelae including gross motor and cognitive impairment. (See <a class="local">'Follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemoprophylaxis</strong> – Chemoprophylaxis is indicated for certain close contacts of patients with meningococcal  (<a class="graphic graphic_table graphicRef51944" href="/z/d/graphic/51944.html" rel="external">table 8</a>) and Hib meningitis. (See  <a class="medical medical_review" href="/z/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection", section on 'Postexposure chemoprophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Antimicrobial chemoprophylaxis'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Maconochie IK, Bhaumik S. Fluid therapy for acute bacterial meningitis. Cochrane Database Syst Rev 2014; :CD004786.</a></li><li><a class="nounderline abstract_t">Olarte L, Barson WJ, Barson RM, et al. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children. Clin Infect Dis 2015; 61:767.</a></li><li class="breakAll">Kim KS. Bacterial meningitis beyond the neonatal period. In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 8th, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier, Philadelphia 2019. p.309.</li><li class="breakAll">American Academy of Pediatrics. Haemophilus influenzae infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.345.</li><li class="breakAll">American Academy of Pediatrics. Meningococcal infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.519.</li><li class="breakAll">American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.639.</li><li><a class="nounderline abstract_t">Finberg RW, Moellering RC, Tally FP, et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 2004; 39:1314.</a></li><li><a class="nounderline abstract_t">Friedland IR, Paris M, Ehrett S, et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993; 37:1630.</a></li><li><a class="nounderline abstract_t">Cherubin CE, Marr JS, Sierra MF, Becker S. Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults. Am J Med 1981; 71:199.</a></li><li><a class="nounderline abstract_t">Hieber JP, Nelson JD. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med 1977; 297:410.</a></li><li><a class="nounderline abstract_t">Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.</a></li><li><a class="nounderline abstract_t">Tan TQ, Schutze GE, Mason EO Jr, Kaplan SL. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1994; 38:918.</a></li><li><a class="nounderline abstract_t">Hameed N, Tunkel AR. Treatment of Drug-resistant Pneumococcal Meningitis. Curr Infect Dis Rep 2010; 12:274.</a></li><li><a class="nounderline abstract_t">Klugman KP, Walsh AL, Phiri A, Molyneux EM. Mortality in penicillin-resistant pneumococcal meningitis. Pediatr Infect Dis J 2008; 27:671.</a></li><li><a class="nounderline abstract_t">McNamara LA, Potts C, Blain AE, et al. Detection of Ciprofloxacin-Resistant, β-Lactamase-Producing Neisseria meningitidis Serogroup Y Isolates - United States, 2019-2020. MMWR Morb Mortal Wkly Rep 2020; 69:735.</a></li><li><a class="nounderline abstract_t">Taormina G, Campos J, Sweitzer J, et al. β-Lactamase-Producing, Ciprofloxacin-Resistant Neisseria meningitidis Isolated From a 5-Month-Old Boy in the United States. J Pediatric Infect Dis Soc 2021; 10:379.</a></li><li><a class="nounderline abstract_t">Oliver SE, Rubis AB, Soeters HM, et al. Secondary Cases of Invasive Disease Caused by Encapsulated and Nontypeable Haemophilus influenzae - 10 U.S. Jurisdictions, 2011-2018. MMWR Morb Mortal Wkly Rep 2023; 72:386.</a></li><li><a class="nounderline abstract_t">Aguilar J, Urday-Cornejo V, Donabedian S, et al. Staphylococcus aureus meningitis: case series and literature review. Medicine (Baltimore) 2010; 89:117.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007; 51:379.</a></li><li><a class="nounderline abstract_t">Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50:3971.</a></li><li><a class="nounderline abstract_t">Villani P, Regazzi MB, Marubbi F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002; 46:936.</a></li><li><a class="nounderline abstract_t">Yogev R, Damle B, Levy G, Nachman S. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J 2010; 29:827.</a></li><li><a class="nounderline abstract_t">Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007; 41:296.</a></li><li><a class="nounderline abstract_t">Kaplan SL, Patrick CC. Cefotaxime and aminoglycoside treatment of meningitis caused by gram-negative enteric organisms. Pediatr Infect Dis J 1990; 9:810.</a></li><li><a class="nounderline abstract_t">Fong IW, Tomkins KB. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7:604.</a></li><li><a class="nounderline abstract_t">Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995; 39:1140.</a></li><li><a class="nounderline abstract_t">Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206.</a></li><li><a class="nounderline abstract_t">Molyneux E, Nizami SQ, Saha S, et al. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. Lancet 2011; 377:1837.</a></li><li><a class="nounderline abstract_t">Karageorgopoulos DE, Valkimadi PE, Kapaskelis A, et al. Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children. Arch Dis Child 2009; 94:607.</a></li><li><a class="nounderline abstract_t">Jadavji T, Biggar WD, Gold R, Prober CG. Sequelae of acute bacterial meningitis in children treated for seven days. Pediatrics 1986; 78:21.</a></li><li><a class="nounderline abstract_t">Snape MD, Kelly DF. Fine with five? Shorter antibiotic courses for childhood meningitis. Lancet 2011; 377:1809.</a></li><li><a class="nounderline abstract_t">Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy. Clin Infect Dis 2019; 68:e1.</a></li><li><a class="nounderline abstract_t">Waler JA, Rathore MH. Outpatient management of pediatric bacterial meningitis. Pediatr Infect Dis J 1995; 14:89.</a></li><li><a class="nounderline abstract_t">Outpatient management of bacterial meningitis. Pediatr Infect Dis J 1989; 8:258.</a></li><li><a class="nounderline abstract_t">Tice AD, Strait K, Ramey R, Hoaglund PA. Outpatient parenteral antimicrobial therapy for central nervous system infections. Clin Infect Dis 1999; 29:1394.</a></li><li><a class="nounderline abstract_t">Bradley JS, Ching DK, Phillips SE. Outpatient therapy of serious pediatric infections with ceftriaxone. Pediatr Infect Dis J 1988; 7:160.</a></li><li><a class="nounderline abstract_t">Lin TY, Nelson JD, McCracken GH Jr. Fever during treatment for bacterial meningitis. Pediatr Infect Dis 1984; 3:319.</a></li><li><a class="nounderline abstract_t">Oliveira CR, Morriss MC, Mistrot JG, et al. Brain magnetic resonance imaging of infants with bacterial meningitis. J Pediatr 2014; 165:134.</a></li><li><a class="nounderline abstract_t">Lieb G, Krauss J, Collmann H, et al. Recurrent bacterial meningitis. Eur J Pediatr 1996; 155:26.</a></li><li><a class="nounderline abstract_t">Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364:2016.</a></li><li><a class="nounderline abstract_t">Arditi M, Mason EO Jr, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998; 102:1087.</a></li><li><a class="nounderline abstract_t">Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997; 337:970.</a></li><li><a class="nounderline abstract_t">Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993; 12:389.</a></li><li><a class="nounderline abstract_t">Mongelluzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids and mortality in children with bacterial meningitis. JAMA 2008; 299:2048.</a></li><li><a class="nounderline abstract_t">Nigrovic LE, Kuppermann N, Malley R, Bacterial Meningitis Study Group of the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med 2008; 15:522.</a></li><li><a class="nounderline abstract_t">Husain E, Chawla R, Dobson S, et al. Epidemiology and outcome of bacterial meningitis in Canadian children: 1998-1999. Clin Invest Med 2006; 29:131.</a></li><li><a class="nounderline abstract_t">Casado-Flores J, Aristegui J, de Liria CR, et al. Clinical data and factors associated with poor outcome in pneumococcal meningitis. Eur J Pediatr 2006; 165:285.</a></li><li><a class="nounderline abstract_t">Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009; 360:244.</a></li><li><a class="nounderline abstract_t">Kornelisse RF, Westerbeek CM, Spoor AB, et al. Pneumococcal meningitis in children: prognostic indicators and outcome. Clin Infect Dis 1995; 21:1390.</a></li><li><a class="nounderline abstract_t">Bohr V, Rasmussen N, Hansen B, et al. Pneumococcal meningitis: an evaluation of prognostic factors in 164 cases based on mortality and on a study of lasting sequelae. J Infect 1985; 10:143.</a></li><li><a class="nounderline abstract_t">Chávez-Bueno S, McCracken GH Jr. Bacterial meningitis in children. Pediatr Clin North Am 2005; 52:795.</a></li><li><a class="nounderline abstract_t">Roine I, Peltola H, Fernández J, et al. Influence of admission findings on death and neurological outcome from childhood bacterial meningitis. Clin Infect Dis 2008; 46:1248.</a></li><li><a class="nounderline abstract_t">Fortnum HM. Hearing impairment after bacterial meningitis: a review. Arch Dis Child 1992; 67:1128.</a></li><li><a class="nounderline abstract_t">Wald ER, Kaplan SL, Mason EO Jr, et al. Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group. Pediatrics 1995; 95:21.</a></li><li><a class="nounderline abstract_t">Dodge PR, Davis H, Feigin RD, et al. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med 1984; 311:869.</a></li><li><a class="nounderline abstract_t">Pelkonen T, Roine I, Monteiro L, et al. Risk factors for death and severe neurological sequelae in childhood bacterial meningitis in sub-Saharan Africa. Clin Infect Dis 2009; 48:1107.</a></li><li><a class="nounderline abstract_t">Roine I, Weisstaub G, Peltola H, LatAm Bacterial Meningitis Study Group. Influence of malnutrition on the course of childhood bacterial meningitis. Pediatr Infect Dis J 2010; 29:122.</a></li><li><a class="nounderline abstract_t">Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006; 118:e979.</a></li><li><a class="nounderline abstract_t">Taylor HG, Schatschneider C, Watters GV, et al. Acute-phase neurologic complications of Haemophilus influenzae type b meningitis: association with developmental problems at school age. J Child Neurol 1998; 13:113.</a></li><li><a class="nounderline abstract_t">Lebel MH, McCracken GH Jr. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics 1989; 83:161.</a></li><li><a class="nounderline abstract_t">Rodenburg-Vlot MB, Ruytjens L, Oostenbrink R, et al. Systematic Review: Incidence and Course of Hearing Loss Caused by Bacterial Meningitis: In Search of an Optimal Timed Audiological Follow-up. Otol Neurotol 2016; 37:1.</a></li><li><a class="nounderline abstract_t">Roine I, Pelkonen T, Cruzeiro ML, et al. Fluctuation in hearing thresholds during recovery from childhood bacterial meningitis. Pediatr Infect Dis J 2014; 33:253.</a></li><li><a class="nounderline abstract_t">Gaschignard J, Levy C, Chrabieh M, et al. Invasive pneumococcal disease in children can reveal a primary immunodeficiency. Clin Infect Dis 2014; 59:244.</a></li><li><a class="nounderline abstract_t">Kaplan SL, Barson WJ, Lin PL, et al. Invasive Pneumococcal Disease in Children's Hospitals: 2014-2017. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Ratilal BO, Costa J, Pappamikail L, Sampaio C. Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev 2015; :CD004884.</a></li></ol></div><div id="topicVersionRevision">Topic 6010 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24793545" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fluid therapy for acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25972022" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25972022" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25972022" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25972022" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25972022" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494908" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The importance of bactericidal drugs: future directions in infectious disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215275" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7020416" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/882110" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A pharmacologic evaluation of penicillin in children with purulent meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494903" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Practice guidelines for the management of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8067771" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21308542" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of Drug-resistant Pneumococcal Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520964" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mortality in penicillin-resistant pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32555137" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Detection of Ciprofloxacin-Resistant,β-Lactamase-Producing Neisseria meningitidis Serogroup Y Isolates - United States, 2019-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32743638" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : β-Lactamase-Producing, Ciprofloxacin-Resistant Neisseria meningitidis Isolated From a 5-Month-Old Boy in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37053119" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Secondary Cases of Invasive Disease Caused by Encapsulated and Nontypeable Haemophilus influenzae - 10 U.S. Jurisdictions, 2011-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20517182" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Staphylococcus aureus meningitis: case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043116" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16982782" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11850294" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20442688" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284501" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Linezolid for the treatment of patients with central nervous system infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2263430" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cefotaxime and aminoglycoside treatment of meningitis caused by gram-negative enteric organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3903939" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7625802" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11376058" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21620467" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628879" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2425333" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sequelae of acute bacterial meningitis in children treated for seven days.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21620468" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fine with five? Shorter antibiotic courses for childhood meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30423035" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7746713" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Outpatient management of pediatric bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2717279" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Outpatient management of bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585784" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Outpatient parenteral antimicrobial therapy for central nervous system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3357713" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Outpatient therapy of serious pediatric infections with ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6473134" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fever during treatment for bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24726712" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Brain magnetic resonance imaging of infants with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8750806" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recurrent bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21612470" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bacterial meningitis in the United States, 1998-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9794939" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9395430" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bacterial meningitis in the United States in 1995. Active Surveillance Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8327300" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Outcomes of bacterial meningitis in children: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18460665" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Corticosteroids and mortality in children with bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616437" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17058430" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Epidemiology and outcome of bacterial meningitis in Canadian children: 1998-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16333641" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical data and factors associated with poor outcome in pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144940" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of pneumococcal conjugate vaccine on pneumococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8749621" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pneumococcal meningitis in children: prognostic indicators and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4008963" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pneumococcal meningitis: an evaluation of prognostic factors in 164 cases based on mortality and on a study of lasting sequelae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15925663" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Bacterial meningitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18444863" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Influence of admission findings on death and neurological outcome from childhood bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1417060" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hearing impairment after bacterial meningitis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7770303" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dexamethasone therapy for children with bacterial meningitis. Meningitis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6472398" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19275501" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Risk factors for death and severe neurological sequelae in childhood bacterial meningitis in sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19934786" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Influence of malnutrition on the course of childhood bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17015517" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Multicenter surveillance of invasive meningococcal infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9535236" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Acute-phase neurologic complications of Haemophilus influenzae type b meningitis: association with developmental problems at school age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2913547" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26649601" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Systematic Review: Incidence and Course of Hearing Loss Caused by Bacterial Meningitis: In Search of an Optimal Timed Audiological Follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24569385" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fluctuation in hearing thresholds during recovery from childhood bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24759830" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Invasive pneumococcal disease in children can reveal a primary immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31420369" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Invasive Pneumococcal Disease in Children's Hospitals: 2014-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25918919" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
